-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$26.0048.4% Upside
Kura Oncology, Inc. Frequently Asked Questions
-
What analysts cover Kura Oncology, Inc.?
Kura Oncology, Inc. has been rated by research analysts at UBS, Stifel Nicolaus, H.C. Wainwright, Mizuho Securities in the past 90 days.